Program
zoldonrasib
Also written as “RMC-9805” and “Zoldonrasib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by Revolution Medicines.
Furthest: phase 3, since May 26, 20266 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Revolution Medicines | 66 open or running | phase 3since May 26, 2026 | Aug 31, 2023 | Dec 31, 2026phase 1 · NCT06040541 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06040541 · 604 planned · United States
- Nov 30, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06162221 · 616 planned · United States, Australia, Austria and more
- May 20, 2024Phase 2 study in Colorectal NeoplasmsNCT06445062 · 1,130 planned · United States
- May 26, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07621718 · 670 planned · United States, Austria, Italy and more
- Aug 17, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07777822 · 430 planned · United States
- Sep 1, 2026Phase 3 study in Pancreatic NeoplasmsNCT07805954 · 400 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06040541
- Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06162221
- Sep 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06445062
- Dec 30, 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07621718
TargetBeta
KRAS →read by rule
“An orally bioavailable covalent tri-complex inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07805954Pancreatic Neoplasms · United States | 3 | Recruiting | Mar 2029 | 400 |
| NCT07777822Carcinoma, Non-Small-Cell Lung · United States | 3 | Recruiting | Oct 2029 | 430 |
| NCT07621718Pancreatic Neoplasms · United States, Austria, Italy and more | 3 | Recruiting | Dec 30, 2028 | 670 |
| NCT06445062Colorectal Neoplasms · United States | 2 | Recruiting | Sep 30, 2028 | 1,130 |
| NCT06162221Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 2 | Recruiting | Jun 2027 | 616 |
| NCT06040541Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Dec 31, 2026 | 604 |
How it is read
Names in the registry
- “RMC-9805”, 3 entries
- “zoldonrasib”, 2 entries
- “Zoldonrasib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Pancreatic Neoplasms, 2 studies
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.